Rhythm Pharmaceuticals, Inc.
RYTM
$52.34
$1.372.69%
| Weiss Ratings | RYTM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | RYTM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | RYTM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 2.08 | |||
| Price History | RYTM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 1.36% | |||
| 30-Day Total Return | -11.93% | |||
| 60-Day Total Return | -5.27% | |||
| 90-Day Total Return | 6.79% | |||
| Year to Date Total Return | -12.87% | |||
| 1-Year Total Return | 30.85% | |||
| 2-Year Total Return | 187.11% | |||
| 3-Year Total Return | 435.72% | |||
| 5-Year Total Return | 297.72% | |||
| 52-Week High % Change | -25.68% | |||
| 52-Week Low % Change | 44.92% | |||
| Price | RYTM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $68.58 | |||
| 52-Week Low Price | $35.17 | |||
| 52-Week Low Price (Date) | May 29, 2024 | |||
| 52-Week High Price (Date) | Nov 11, 2024 | |||
| Valuation | RYTM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 3.22B | |||
| Enterprise Value | 3.16B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -4.36 | |||
| Earnings Per Share Growth | 35.92% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 24.13 | |||
| Price/Book (Q) | 146.34 | |||
| Enterprise Value/Revenue (TTM) | 24.27 | |||
| Price | $52.34 | |||
| Enterprise Value/EBITDA (TTM) | -11.97 | |||
| Enterprise Value/EBIT | -11.90 | |||
| Market Cap Category | Mid Cap | |||
| Dividends and Shares | RYTM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 61.60M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | RYTM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 857 264 4280 | |||
| Address | 222 Berkeley Street Boston, MA 02116 | |||
| Website | rhythmtx.com | |||
| Country | United States | |||
| Year Founded | 2008 | |||
| Profitability | RYTM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -204.03% | |||
| Profit Margin | -200.24% | |||
| Management Effectiveness | RYTM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -45.78% | |||
| Return on Equity | -- | |||
| Income Statement | RYTM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 130.13M | |||
| Total Revenue (TTM) | 130.13M | |||
| Revenue Per Share | $2.11 | |||
| Gross Profit (TTM) | 116.76M | |||
| EBITDA (TTM) | -263.94M | |||
| EBIT (TTM) | -265.51M | |||
| Net Income (TTM) | -260.57M | |||
| Net Income Avl. to Common (TTM) | -260.57M | |||
| Total Revenue Growth (Q YOY) | 72.61% | |||
| Earnings Growth (Q YOY) | -3.98% | |||
| EPS Diluted (TTM) | -4.36 | |||
| EPS Diluted Growth (Q YOY) | -3.06% | |||
| Balance Sheet | RYTM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 320.57M | |||
| Cash Per Share (Q) | $5.20 | |||
| Total Current Assets (Q) | 374.20M | |||
| Total Preferred Equity (Q) | 142.82 | |||
| Total Equity (Q) | 164.55M | |||
| Current Ratio (Q) | 3.239 | |||
| Book Value Per Share (Q) | $0.35 | |||
| Total Assets (Q) | 392.27M | |||
| Total Current Liabilities (Q) | 115.52M | |||
| Total Debt (Q) | 113.75M | |||
| Total Liabilities (Q) | 227.72M | |||
| Total Common Equity (Q) | 21.73M | |||
| Cash Flow | RYTM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -48.17M | |||
| Cash from Financing (TTM) | 191.24M | |||
| Net Change in Cash (TTM) | 29.19M | |||
| Levered Free Cash Flow (TTM) | -160.75M | |||
| Cash from Operations (TTM) | -113.88M | |||
